3Di-Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels ischemic stroke [J]. Stroke, 2001 ; 32 (1) :133-8.
6Taogoshi T, Nomura A, Murakami T, et al. Transport of prostaglandin E1 across the blood-brain barrier in rats [J]. J Pharm Pharmacol, 2005 ; 57 (1) :61-6.
7Kikuchi S, Shinpo K, Niino M, et al. Prostaglandin El protects cultured spinal neurons against the effects of nitric oxide toxicity [J]. Neuropharmacology ,2002 ;42 (5) :714-23.
6US Departmentof Healthand Human Services Monograph，1996年，30页
7Hatanaka K，Pathol Int，1995年，45卷，631页
8Liuzzo G，New Engl J Med，1994年，331卷，417页
9Young W, Rappaport ZH, Chalit DJ, et al. Regional brain sodium, potassium and water changes in the rat middle cerebral artery occlusion model of ischemia[J]. Stroke, 1987, 18: 751.
10Ney P, Braun M, Szymanski C, et al. Antiplatelet, antineutrophil and vasodilating properties of 13, 14-Dihydro-PGE1-an in vivo metabol ite of PGE1 in man[ J ]. Endocrinology, 1994, 4: 77.
7Lehto S, Ronnemaa T, Pyorala K, et al, Predictors of stroke in middle aged patients with non-insulin-dependent diabetes [ J]. Stroke, 1996,27 (1) :63-68.
8Yegen M, Osteson CG, Hu H , et al. Enhanced P-secleetin expression and increased soluble CD40 ligand in patients with type 1 diabetes rnellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation [ J ]. Diabetologia,2004,4799 (2) :537-540.
9Sainani GS, Mara VG, Role of endothelial cell dysfunction inessential hypertension [ J ]. J Assoc Physicians India,2004,52:966-969.
